article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.

article thumbnail

PicnicHealth Acquires AllStripes, Fortifying its Role as the Leader in Patient-Centered Healthcare Evidence Generation

Healthcare IT Today

PicnicHealth , a patient-centered healthcare evidence generation company, today announced the acquisition of AllStripes , a platform dedicated to generating evidence about the rare disease community. The focus of the solutions will be making clinical research and registry development more effective and efficient.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Where are HealthTech's soft landing M&A deals in today's market?

Lloyd Price

AI and machine learning: Companies with advanced AI solutions for tasks like drug discovery, clinical trial optimisation, and personalised medicine can be attractive targets. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.

article thumbnail

AngelEye Health Announces Series B Funding to Support Company’s Rapid Growth

Healthcare IT Today

Mountain Group Partners is an investor dedicated to investing in and actively guiding transformational businesses in the Technology, Animal Health, and Life Sciences sectors. Technology investments focus on business and healthcare technology, targeting those ideas with quantifiable development risk and a rapid path to market.

article thumbnail

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Digital Health Global

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. and Europe.

BioTech 88